【医美专栏】东方妍美赴港冲刺IPO，专注再生医学材料和特医食品！

Core Viewpoint - Eastenova (Chengdu) Biotechnology Co., Ltd. is planning an IPO on the Hong Kong Stock Exchange, focusing on regenerative medical materials and special medical foods [2][4]. Company Overview - Established in 2016 and located in Chengdu, the company specializes in the research, production, and commercialization of regenerative medical devices and special medical foods [4]. - The product portfolio includes regenerative medical materials and special medical foods, with two main product lines: regenerative medical material injectables and medical dressings and patches [4]. Product Development - The company is advancing the development of eight candidate products currently in clinical or registration review stages, including core product XH301 and XH305, which is under registration review by the National Medical Products Administration [6]. - The company is also preparing to submit an application for EU CE mark certification for core product XH301 [6]. - In the regenerative medical material injectables category, the company has 13 candidate products, all classified as Class III medical devices, with XH301 targeting nasolabial folds and XH321 for female stress urinary incontinence [9]. Financial Performance - In 2023 and 2024, the company's projected revenues are 12.882 million and 14.520 million respectively, with R&D costs of 45.726 million and 44.950 million for the same years [8]. - The net losses for these years are expected to be 63.501 million and 69.380 million respectively [8]. Special Medical Foods - The company has received approval for two special medical food products, with seven additional products currently in development, including three specific complete nutrition formula foods [7].